Epigenic Therapeutics

Executive Summary

Epigenic Therapeutics is a preclinical-stage biotechnology company pioneering novel epigenetic therapies for cancer. Founded in 2021 and headquartered in Cambridge, MA, the company has raised $92 million to develop small molecule inhibitors that target key epigenetic regulators, aiming to reverse aberrant gene expression in tumors. By modulating the tumor microenvironment and enhancing immune recognition, Epigenic seeks to achieve durable responses in hard-to-treat cancers. Its platform leverages proprietary insights into epigenetic reprogramming, positioning it as a potential leader in the emerging field of epigenetic oncology. As a preclinical company, Epigenic's near-term value hinges on advancing its lead candidates into clinical development. The company is expected to file an Investigational New Drug (IND) application for its most advanced program within the next 12-18 months, followed by the initiation of Phase I trials. Success in early clinical proof-of-concept could unlock significant upside, though risks remain high given the unvalidated nature of the approach and competitive landscape. With a strong funding base and experienced management, Epigenic is well-positioned to execute its pipeline milestones.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Epigenetic Inhibitor70% success
• Q4 2026Initiation of Phase 1 Clinical Trial60% success
• Q2 2026Preclinical Data Presentation at Major Oncology Conference80% success